Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force
Jin Liu1, Gregory E R Weller, Blaine Zern
1Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
Summary
A new computational model accurately predicts nanocarrier binding to cells, crucial for targeted drug delivery. It reveals an optimal antibody coverage threshold for effective nanocarrier (NC) binding to endothelial cells (EC).
Area of Science:
- Computational biology
- Biophysics
- Nanotechnology
Background:
- Targeted drug delivery relies on nanocarriers (NCs) binding to specific cell surfaces.
- Understanding the biophysical interactions between NCs and endothelial cells (ECs) is critical for optimizing NC design.
Purpose of the Study:
- To develop and validate a computational methodology for calculating nanocarrier binding free energy to endothelial cells.
- To investigate the impact of antibody surface coverage on nanocarrier binding affinity and identify optimal coverage thresholds.
Main Methods:
- Utilized Metropolis Monte Carlo (MC) simulations and the Weighted Histogram Analysis Method (WHAM) to compute binding free energy.
- Validated computational models against in vitro cell-culture experiments, in vivo animal studies, and atomic force microscopy (AFM) measurements.
Main Results:
- The computational model quantitatively predicts nanocarrier binding affinities, showing strong agreement with experimental data.
- A critical threshold for antibody surface coverage (σ(s)) was identified, below which binding affinity drastically decreases.
- Model predictions for NC rupture force and in vivo targeting align well with experimental observations.
Conclusions:
- The developed computational protocol provides a quantitative and predictive approach for designing and optimizing functionalized nanocarriers.
- This methodology establishes the mechanical, thermodynamic, and physiological consistency of nanocarrier-cell interactions.
- The findings are crucial for advancing targeted vascular drug delivery systems.


